Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 6/20 | 0.53 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 3/20 | 0.45 |
| ▸ | BRD4 | O60885 | 2/20 | 0.45 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.44 |
| ▸ | SYK | P43405 | 2/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 2/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633108 | 0.98 | PTK2 (0.51) | PTK2IGF1RAURKAAURKBJAK2 | |
| SCHEMBL1634490 | 0.90 | PTK2 (0.55) | PTK2AURKAAURKBJAK2BRD4 | |
| SCHEMBL1633745 | 0.89 | TBK1 (0.53) | PTK2IGF1RAURKAAURKBJAK2 | |
| SCHEMBL1633332 | 0.88 | PTK2 (0.53) | PTK2AURKAAURKBJAK2BRD4 | |
| SCHEMBL1632937 | 0.88 | PTK2 (0.51) | PTK2AURKAAURKBJAK2BRD4 | |
| SCHEMBL1633607 | 0.83 | JAK2 (0.51) | PTK2AURKAJAK2SYKJAK1 | |
| SCHEMBL1633209 | 0.83 | JAK2 (0.61) | PTK2AURKAAURKBJAK2BRD4 | |
| SCHEMBL1632091 | 0.83 | IKBKB (0.47) | IGF1RJAK2SYKJAK1TYK2 | |
| SCHEMBL1633501 | 0.82 | LRRK2 (0.51) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL1632897 | 0.81 | AURKA (0.56) | PTK2IGF1RAURKAAURKBBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | PTK2 560/4885IGF1R 629/4885AURKA 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.